ASSESSMENT OF HAPPY HYPOXIA CASES OBSERVED IN MEDICAL HOSPITALS OVER A PERIOD OF 6 MONTHS

Main Article Content

Dr Kandy Sandhu
Dr Harnoor Singh Sandhu
Dr Sahib Sharma
Dr Nidha Naib
Dr Kanwarshabaz Singh Sandhu
Dr Avineet Kaur

Keywords

COVID-19, Diabetes mellitus, Happy hypoxia, Oxygen Saturation, Prevalence, Vitals

Abstract

Aim: To assess happy hypoxia cases observed in medical hospitals.


Methodology: One hundred twenty- eight cases of happy hypoxia involving both genders were included. Clinical symptoms, laboratory parameters and the level of PaO2, PaO2:FIO2 and PaCO2 level was recorded.


Results: Out of 128 patients, males were 78 (61%) and females were 50 (39%). BMI found to be <18.5 kg/m2 in 35, 18.5-24.9 kg/m2 in 32 and >24.9 kg/m2 in 65. Clinical features comprise of fever in 128, nausea/vomiting in 93, abdominal pain in 45, diarrhea in 39 and breathlessness in 114. Co- morbidities were diabetes mellitus in 62, CKD in 14, chronic liver disease in 6, malignancy in 5, COPD in 54, hypertension in 67 and smoking in 45. Vitals recorded was heart rate was 114.6 beats/minute, respiratory rate 32.5 cycles/minute and mean arterial pressure (MAP) 36.4 mm Hg. WBC found to be 15.2X109/L, neutrophil 4.9 X109/L, lymphocyte 8.3 X109/L, monocyte 1.6 X109/L and platelets 162 X109/L. d- dimer was 2890 mg/dl, LDH was 872.4 U/L and IL- 6 was 112.7. The mean prothrombin time recorded was 19.2 seconds and PTT was 42.8 seconds. The mortality cases were 65 (50.7%). The difference was significant (P< 0.05). The mean PaO2 was 58.2%, PaO2:FIO2 was 134.7% and PaCO2 was 60.4%. Out of 65 mortality cases (50.7%), the risk factors found to be BMI >24.9 kg/m2 in 45, age >65 years in 56, diabetes mellitus in 38, CKD in 11, PaO2 <65% in 36 and d- dimer >2500 mg/dl in 57 cases.


Conclusion: The mortality rate found to be 50.9%. Risk factors of mortality in happy hypoxemia cases was age >65 years, BMI >24.9 kg/m2, diabetes mellitus, CKD, PaO2 <65% and d- dimer >2500 mg/dl.

Abstract 98 | pdf Downloads 45

References

1. Sirohiya P, Elavarasi A, Sagiraju HKR, et al.(2021) Silent Hypoxia in Coronavirus disease-2019: is it more dangerous? -A retrospective cohort study. medRxiv preprint.
2. World Health Organization. Coronavirus (COVID-19) Dashboard.(2022) Available from: https://covid19.who.int/. Accessed August 30.
3. García-Grimshaw M, Flores-Silva FD, Chiquete E, et al.(2021) Characteristics and predictors for silent hypoxemia in a cohort of hospitalized COVID-19 patients. AutonNeurosci. ;235:102855.
4. Stang A.(2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605.
5. Rahman AE, Hossain AT, Nair H, et al.(2022) Prevalence of hypoxemia in children with pneumonia in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Glob Health. 10(3):e348–e359.
6. Cardona S, Downing J, Alfalasi R, et al.(2021) Intubation rate of patients with hypoxia due to COVID-19 treated with awakeproning: a meta-analysis. Am J Emerg Med. 43:88–96.
7. Mohammadi M, Khafaee Pour Khamseh A, Varpaei HA.(2021) Invasive Airway “Intubation” in COVID-19 patients; statistics, causes, and recommendations: a review article. Anesth Pain Med.11(3):115868.
8. O’Donnell CR, Friedman LS, Russomanno JH, Rose RM.(1988) Diminished perception of inspiratory-resistive loads in insulin-dependent diabetics. N Engl J Med.319 (November (21)):1369–1373.
9. Cretikos MA, Bellomo R, Hillman K, Chen J, Finfer S, Flabouris A.(2008) Respiratory rate: the neglected vital sign. Med J Aust.188(11):657–659.
10. Klok FA, Kruip MJHA, van der Meer NJM, et al.(2020) Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 191:148–150.
11. Iba T, Gando S, Thachil J.(2014) Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J ThrombHaemost. 12:1010–1019.
12. Guan WJ, Ni ZY, Hu Y, et al.(2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382(18):1708–1720.
13. Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A.(2020) Pulmonary and extra-pulmonary clinical manifestations of COVID-19. Front Med. 7:526.
14. Goyal P, Choi JJ, Pinheiro LC, et al.(2020) Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372–2374.
15. Gallo Marin B, Aghagoli G, Lavine K, et al. (2021)Predictors of COVID-19 severity: a literature review. Rev Med Virol. 31(1):1–10.
16. Levitan R. (2022)The infection That’s silently killing coronavirus patients; 2010. Available from:https://www.nytimes.com/2020/04/20/opinion/sunday/coronavirus-testing-pneumonia.html/. Accessed April 12, 2022.
17. Akiyama Y, Morioka S, Asai Y, et al.(2022) Risk factors associated with asymptomatic hypoxemia among COVID-19 patients: a retrospective study using the nationwide Japanese registry, COVIREGI-JP. J Infect Public Health. 15(3):312–314
18. Bepouka B, Odio O, Mayasi N, Longokolo M, Mangala D, Mandina M, Mbula M, Kayembe JM, Situakibanza H. (2022) Prevalence and Outcomes of COVID− 19 Patients with Happy Hypoxia: A Systematic Review. Infection and Drug Resistance. 2022 Sep 22;15:5619-28.
19. Sirohiya P, Elavarasi A, Sagiraju HKR, et al.(2021) Silent Hypoxia in Coronavirus disease-2019: is it more dangerous? -A retrospective cohort study. medRxiv preprint.
20. Alhusain F, Alromaih A, Alhajress G, et al.(2021) Predictors and clinical outcomes of silent hypoxia in COVID-19 patients, a single-center retrospective cohort study. J Infect Public Health. 14(11):1595–1599.
21. Busana M, Gasperetti A, Giosa L, et al.(2021) Prevalence and outcome of silent hypoxemia in COVID-19. Minerva Anestesiol. 87(3):325–333.

Most read articles by the same author(s)